AstraZeneca PLC or Genmab A/S: Who Manages SG&A Costs Better?

AstraZeneca PLC vs. Genmab A/S: A Decade of SG&A Management

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, AstraZeneca PLC and Genmab A/S have demonstrated contrasting approaches to SG&A cost management. AstraZeneca, a global leader, has consistently reported higher SG&A expenses, peaking at approximately $18 billion in 2022. This reflects its expansive operations and aggressive marketing strategies. In contrast, Genmab A/S, a smaller biotech firm, has maintained a leaner structure, with SG&A expenses growing from $80 million in 2014 to around $3.3 billion in 2023. This represents a significant increase, yet it remains a fraction of AstraZeneca's costs. The data suggests that while AstraZeneca's scale demands higher expenditures, Genmab's growth trajectory is marked by strategic investments in administrative efficiency. As the industry evolves, these companies' SG&A strategies will continue to shape their financial health and market positions.